[Iscalimab-New Treatment Option for Patients with Primary Sjögren's Disease]

Ritter J, Chen Y, Stefanski A, Dorner T . Current and future treatment in primary Sjögren's syndrome - A still challenging development. Joint Bone Spine. 2022; 89(6):105406. DOI: 10.1016/j.jbspin.2022.105406. View

Fisher B, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng W . Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Lancet. 2024; 404(10452):540-553. DOI: 10.1016/S0140-6736(24)01211-X. View

Seror R, Theander E, Brun J, Ramos-Casals M, Valim V, Dorner T . Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis. 2014; 74(5):859-66. DOI: 10.1136/annrheumdis-2013-204615. View